Asset
Prulacabtagene Leucel
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04735471 | phase1 | terminated | 2021-03-04 | 2025-02-03 | Adicet Therapeutics | A Phase 1 Study of ADI-001 in B Cell Malignancies |
| NCT07100873 | phase1 | recruiting | 2025-10-10 | 2027-03-30 | Adicet Therapeutics | A Phase 1 Study of ADI-001 in Rheumatoid Arthritis |
| NCT06375993 | phase1 | enrolling_by_invitation | 2024-11-10 | 2026-12-01 | Adicet Therapeutics | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease |
FDA applications (0)
This company has no applications containing this asset.